Results 61 to 70 of about 154,650 (346)
Drug-Induced Steatohepatitis [PDF]
Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in the United States. The term NALFD was first used by Ludwig in 1980 to describe the presence of hepatic steatosis and steatohepatitis in a series of patients with no identifiable cause.
Vaishali, Patel, Arun J, Sanyal
openaire +2 more sources
Adaptive mitochondrial mechanisms allow mitochondrial resilience and prevent the worsening of fibrosis, while deregulation of these mechanisms promotes the progression from no/minimal‐mild (F0‐F2) fibrosis to advanced fibrosis and cirrhosis (F3‐F4). Abstract Background and Aims Hepatitis B virus (HBV) infection causes oxidative stress (OS) and alters ...
Dimitri Loureiro +17 more
wiley +1 more source
The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease
Alcoholic liver disease (ALD) encompasses hepatic steatosis, which may progress to alcoholic hepatitis, fibrosis, and cirrhosis. It remains a leading cause of morbidity and mortality in the US and worldwide.
Phillipp eHartmann +2 more
doaj +1 more source
BACKGROUND AND AIMS Nonalcoholic fatty liver disease (NAFLD) now known as metabolic dysfunction associated steatotic liver disease (MASLD) is closely associated with type 2 diabetes (T2D).
Z. Younossi +6 more
semanticscholar +1 more source
BACKGROUND & AIMS The profile of chronic liver disease (CLD) in the United States has changed due to obesity trends and advances in treatment of viral hepatitis. We assessed liver transplant listing trends by CLD etiology.
Z. Younossi +8 more
semanticscholar +1 more source
Simple Summary In the context of liver disease, one of the more growing public health problems is the transition from simple steatosis to non-alcoholic steatohepatitis.
S. Todisco +6 more
semanticscholar +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Background & Aims: Excessive alcohol consumption accelerates fibrosis progression in steatotic liver disease. Disease activity can be described by fibrogenic activity, of which collagen formation is a central process. Type III collagen formation (PRO-
Stine Johansen +14 more
doaj +1 more source
Non-alcoholic steatohepatitis (NASH) is a major cause of chronic liver disease. However, most available animal models fail to reflect the whole spectrum of the disease.
Raquel Maeso-Díaz +6 more
doaj +1 more source
Steatohepatitis Associated with Limb Lipodystrophy
Two patients who presented with steatohepatitis had acquired partial lipodystrophy. This association has not previously been well documented. A common pathophysiological mechanism in lipodystrophy, obesity-associated nonalcoholic steatohepatitis, and ...
Powell, Elizabeth E. +5 more
core +1 more source

